Proteomic Analysis of Dorsal Root Ganglia in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Rania HannaAlexandru GraurPatricia SinclairBryan D MckiverM Paula D BosM Imad DamajNadine KabbaniPublished in: bioRxiv : the preprint server for biology (2024)
Paclitaxel is a chemotherapy drug widely used for the treatment of various cancers based on its ability to potently stabilize cellular microtubules and block division in cancer cells. Paclitaxel-based treatment, however, accumulates in peripheral system sensory neurons and leads to a high incidence rate (over 60%) of chemotherapy induced peripheral neuropathy. Using an established preclinical model of paclitaxel-induced peripheral neuropathy (PIPN), we examined proteomic changes in dorsal root ganglia (DRG) of adult male mice that were treated with paclitaxel (8 mg/kg, at 4 injections every other day) relative to vehicle-treated mice. High throughput proteomics based on liquid chromatography electrospray ionization mass spectrometry identified 165 significantly altered proteins in lumbar DRG. Gene ontology enrichment and bioinformatic analysis revealed an effect of paclitaxel on pathways for mitochondrial regulation, axonal function, and inflammatory purinergic signaling as well as microtubule activity. These findings provide insight into molecular mechanisms that can contribute to PIPN in patients.
Keyphrases
- chemotherapy induced
- neuropathic pain
- mass spectrometry
- spinal cord
- liquid chromatography
- spinal cord injury
- high throughput
- mouse model
- newly diagnosed
- end stage renal disease
- single cell
- chronic kidney disease
- high glucose
- minimally invasive
- oxidative stress
- adipose tissue
- prognostic factors
- metabolic syndrome
- ejection fraction
- emergency department
- mesenchymal stem cells
- genome wide
- radiation therapy
- tandem mass spectrometry
- ms ms
- transcription factor
- solid phase extraction